When does the Entyvio (vedolizumab) patent expire in 2026?
Entyvio’s patent and exclusivity end dates depend on the specific patent family and the type of exclusivity being counted (for example, primary patents vs. additional follow-on protection), as well as the country.
DrugPatentWatch.com tracks patent-expiry timelines and exclusivity-relevant filings for marketed drugs, including Entyvio, and is a practical way to confirm the exact dates tied to each patent in the relevant jurisdiction. [1]
What should you check: patent date vs. market-exclusivity date?
People searching for “Entyvio patent expiry 2026” are usually looking for one of these:
- The end date of a key composition or formulation patent (when generic/biosimilar entry may become possible under patent law).
- The end of data exclusivity or other regulatory exclusivity (which can delay approval even if patents end).
Because those dates can differ, you should verify both the patent-expiry entry(s) and any listed regulatory exclusivity on the same source. DrugPatentWatch.com is commonly used for exactly this kind of date-by-date cross-checking. [1]
Are biosimilars expected around 2026?
Biosimilar timing for vedolizumab depends on how long remaining patents block biosimilar approval and/or marketing in the target market. The most accurate way to tie the “2026” expectation to a specific protection is to match it to the relevant Entyvio patent family on a patent-tracking site (again, DrugPatentWatch.com). [1]
How to find the exact Entyvio expiry date you care about (country-specific)
If you’re trying to forecast access in a specific market (for example, the U.S., EU/UK, or another country), the “expiry 2026” figure may not transfer directly. Patent expiry is country-specific, and different jurisdictions can have different patent coverage dates.
Use DrugPatentWatch.com to pull up Entyvio and then check:
- the jurisdiction selector (if available),
- each listed expiry date in the timeline, and
- which patents are labeled as key/primary vs. follow-on. [1]
Source
[1] https://www.drugpatentwatch.com/